• Increase font size
  • Default font size
  • Decrease font size

As Darling Dendreon Takes Hits Others Continue To Thrive

Print E-mail
Written by Staff and Wire Reports   
Tuesday, 22 May 2012 04:37
Recently considered biotech’s immunotherapy darling, shares of Dendreon Corporation have been taking a beating. Does this mean the end of the road or opportunity for others in the same space?
Read more...
 

Merck H.I.V. Trial Vaccine Stopped; J&J's Xarelto Cited for Missing Data

Print E-mail
Written by Staff and Wire Reports   
Monday, 21 May 2012 18:55
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 21, 2012.
Read more...
 

Frost buys more PROLOR

Print E-mail
Written by M.E.Garza   
Monday, 21 May 2012 05:06
Investors may be a bit weary of jumping into PROLOR Biotech (PBTH) after the company announced the closing an underwritten public offering, but that hasn't kept billionaire Phil Frost-- chairman of generic drugmaker Teva Pharmaceutical Industries (NASDAQ:TEVA)-- from buying another big chunk of the company.
Read more...
 

Perrigo Announces FDA Final Approval and Launch of OTC Lansoprazole; Watson Confirms Patent Challenge

Print E-mail
Written by Staff and Wire Reports   
Friday, 18 May 2012 23:28
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 18, 2012.
Read more...
 

Five Companies in the Casey Portfolio Worth Watching: Alex Daley

Print E-mail
Written by George S. Mack of The Life Sciences Report   
Friday, 18 May 2012 02:38
Biotech and medtech expose investors to rapid growth in healthcare innovation. Chief Investment Strategist Alex Daley of Casey's Extraordinary Technology matches science to unmet needs to bring big ideas and big returns to investors. 
Read more...
 

Boston Scientific Announces FDA Approval of Stem Cell Drug; Osiris Receives Marketing Clearance for Prochymal

Print E-mail
Written by Staff and Wire Reports   
Thursday, 17 May 2012 18:59
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 17, 2012.
Read more...
 

Video Q&A: Brian M. Culley, CEO of Adventrx Pharmaceuticals

Print E-mail
Written by Staff and Wire Reports   
Thursday, 17 May 2012 04:07
Shares of Adventrx Pharmaceuticals Inc (Amex:ANX) are trading -87.41 % from their 52-Wk High ($ 4.21). With two possible pending Phase III trial initiations on-tap and some recent insider buying, it appears the heavily shorted stock may be a good bottom bounce candidate at today's price levels.
Read more...
 

Medtronic Receives Notification of Activities Relating to INFUSE Bone Graft; FDA Receives Repros' Submission Androxal

Print E-mail
Written by Staff and Wire Reports   
Wednesday, 16 May 2012 19:05
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 16, 2012.
Read more...
 

Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter

Print E-mail
Written by George S. Mack of The Life Sciences Report   
Wednesday, 16 May 2012 06:02
Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation.
Read more...
 

Pfizer's Phase III Study Didn't Meet Primary Endpoint; Boston Scientific Announces Positive Data

Print E-mail
Written by Staff and Wire Reports   
Tuesday, 15 May 2012 18:52
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 15, 2012.
Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 237
Twit twit... ops! Something went wrong, try again later!

navigation

Free Phone Trade Alerts

Benzinga.com supporter Seeking Alpha Certified